Takeda

Boston, MA · Zurich, CH
Hybrid — also manufactures internal programs
AAV Cell Therapy
99 confirmed programs · 26 sponsors · Last scored 2026-03-15
61.5
Signal Score
✓ FDA Inspections (2) ✓ Clinical Trials (99) ○ SEC Filings ✓ Press (2)

Quick Facts: Takeda

Signal Score
61.5/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Boston, MA · Zurich, CH
Modalities
AAV, Cell Therapy
Active CGT Programs
99 confirmed from ClinicalTrials.gov across 26 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections2 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-11-12)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 99
Sponsors26
ModalitiesAAV, Cell Therapy
99 active programs across 26 sponsors
Modalities: Cell Therapy, AAV
66 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07422480 A Study to Compare Elritercept With Epoetin Alfa to Treat... PHASE3 Recruiting
NCT07224100 Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib... PHASE2 Recruiting
NCT06980480 A Study of Gammagard Liquid (Immune Globulin Infusion, 10%)... PHASE3 Recruiting
NCT07217301 IBI363 vs Docetaxel in Patients With Advanced Squamous Lung... PHASE3 Recruiting
NCT07205718 A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors PHASE1/PHASE2 Recruiting
NCT06377228 A Study of TAK-007 in Adults With Refractory Lupus Nephritis... PHASE1 Withdrawn
NCT06588868 Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma NA Recruiting
NCT06677892 A Study of Maribavir in Adults With Post-transplant... NA Recruiting
NCT06615921 A Study of Maribavir in Adults With Post-transplant... NA Completed
NCT05952804 IVIG for Infection Prevention After CAR-T-Cell Therapy PHASE2 Recruiting
View all 99 programs →
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 63.0
2 CGT manufacturing sites
Sites: Boston, MA, Zurich, CH
Source: SEC EDGAR, press monitoring, company profiles
2 CGT manufacturing sites
Recent Press2 articles
2 CGT manufacturing sites

FDA Inspection History

2025-11
2024-10
NAI VAI OAI
Date Site Type Observations Classification
2025-11-12 Singen (Hohentwiel) Drug Quality Assurance No Voluntary Action Indicated (VAI)
2024-10-16 Cambridge, Massachusetts Bioresearch Monitoring No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Clinical Activity 99 studies

NCT07422480 A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults... PHASE3 Recruiting NCT07224100 Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the... PHASE2 Recruiting NCT06980480 A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent... PHASE3 Recruiting NCT07217301 IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After... PHASE3 Recruiting NCT07205718 A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors PHASE1/PHASE2 Recruiting NCT06377228 A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or... PHASE1 Withdrawn NCT06588868 Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma NA Recruiting NCT06677892 A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV)... NA Recruiting NCT06615921 A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection NA Completed NCT05952804 IVIG for Infection Prevention After CAR-T-Cell Therapy PHASE2 Recruiting NCT05718297 Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion... PHASE2 Withdrawn NCT05748197 A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia PHASE1 Recruiting NCT05886478 A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With... NA Completed NCT05737849 A Study to Learn About the Tests Looking for a Gene Mutation in Adults With... NA Withdrawn NCT05721950 A Study to Learn About Brigatinib Treatment Information Available in Chinese... NA Active Not Recruiting NCT05319353 A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and... PHASE3 Recruiting NCT05886491 A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1/PHASE2 Active Not Recruiting NCT05571137 A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem... NA Completed NCT05735327 A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small... NA Recruiting NCT05757700 Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People... PHASE1 Active Not Recruiting
+ 79 more studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026

Recent News 2 articles

general 2026-03-18
Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio - Fierce Pharma
Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio  Fierce Pharma
Source →
general 2026-02-23
Cristália Laboratory prepares for a global leap with the drug that has enabled quadriplegics to walk - NeoFeed
Cristália Laboratory prepares for a global leap with the drug that has enabled quadriplegics to walk  NeoFeed
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Cell Therapy CDMOs →